In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $58.00. The company’s shares closed yesterday at $7.66.
Roy covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Cassava Sciences, and Mirati Therapeutics. According to TipRanks, Roy has an average return of -5.8% and a 25.93% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $50.67 average price target.
See today’s best-performing stocks on TipRanks >>
AVXL market cap is currently $627.7M and has a P/E ratio of -11.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More on AVXL:
- Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
- Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
- Anavex appoints Sabbagh as Chairman of the Scientific Advisory Board
- Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
- Anavex reports Q3 EPS (14c), consensus (17c)
